NeoStem

Advances in modern medicine have been significant as scientists fight to prevent and cure the hosts of injuries and diseases plaguing mankind.  Universities, government, pharmaceuticals and biotechs lead the way with new and improved mechanisms of countering these problems.  Billions of...

Life Tech Capital reiterated its Strong Buy rating on NeoStem (NYSE: NBS). At the same time, Life Tech left its price target on the company's stock unchanged at $4. In a research report published today, Life Tech states, "While R&D efforts are ongoing in the U.S., especially with their bone...

LifeTech Capital is maintaining its Strong Buy rating and $4 PT on shares of NeoStem, Inc. (NYSE: NBS). “NeoStem has Record $69.8M in Revenues for 2010,” LifeTech Capital writes. “Suzhou Erye Pharmaceuticals accounted for the majority of revenues in 2010 while new business units, including the...